FTSE 100 Live: London stocks shrug off Iran's Hormuz terms as miners lend support

FTSE 100 was up around 51 points to 10,919 as Brent crude rose above $82 per barrel. Precious metals gains lifted Fresnillo, up about 5%, and Endeavour Mining. The move followed reports of Iran-Oman draft terms on Strait of Hormuz shipping restrictions. Investors also awaited US non-farm payrolls.

Original reporting
Published Aug 7, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$AZN
Bullish
low confidence
Mentioned
$AZN · $RTO
Relevance
6/10
AlphAI data visualization · based on proactiveinvestors.co.uk
Decision brief

The 30-second read

$AZNBullishMed
01

Why it matters

Precious-metals miners are bid on gold and silver strength, while energy names benefit from higher Brent. Separately, several single-stock catalysts appear: Goodwin’s sale exploration, Genel’s takeover rejection and DNO’s public offer, and Oxford BioMedica’s guidance cut.

02

Market read

Traders get both macro-driven commodity beta (gold, silver, Brent) and several company-specific catalysts that can drive outsized intraday moves.

03

What to watch

The article notes unusually wide payroll estimate ranges; a surprise could quickly rotate out of commodity beta and into defensives, reversing early winners.

Relevance 6/10Novelty 5/10Timing: pre-market and early London session, ahead of US non-farm payrolls later today

Background

The piece frames early FTSE 100 trading around Iran-Oman Strait of Hormuz draft terms and an upcoming US non-farm payrolls release, with commodities driving sector moves.

Company-level read

Ticker impact

$AZNBullishLow confidence
Context

AstraZeneca recovers some losses as the risk of a merger with Bristol-Myers Squibb is described as having receded.

Expected impact

Potential for continued stabilization, but likely headline-driven and reversible.

Evidence & confidence

The article frames the move as receding merger risk without new deal terms or a definitive resolution, so incremental information is limited.

$RTOBearishLow confidence
Context

Rentokil Initial is down about 1.6% in early trade while the index is supported by miners and oil strength.

Expected impact

Limited conviction without a fresh catalyst.

Evidence & confidence

The article lists the decliner but does not provide a new company event or driver for RTO.

Market effects

Higher Brent and stronger gold/silver are driving cross-asset beta into miners and energy, while oil-sensitive sectors (airlines) lag.

UK large-caps are trading as a proxy for Middle East shipping risk and US payroll expectations.

Hormuz-related shipping terms and US jobs data can move global rates, inflation expectations, and commodity complex pricing.

Counterpoint

The index strength may be temporary if gold and oil gains fade after Hormuz headlines or if payrolls surprise shifts rate expectations.

Key entities

  • Fresnillo PLC

    Precious-metals miner leading FTSE 100 gains on gold and silver price strength.

  • Goodwin PLC

    Engineering group confirming it is exploring a sale of part of its mechanical engineering division.

  • Genel Energy PLC

    Rejecting a £202 million takeover approach while DNO publishes a 69p-a-share cash offer.

  • Oxford BioMedica PLC

    Cutting 2026 guidance with EBITDA expectations slashed by about half.

  • BP PLC

    Up on Brent crude rising back above the low-$80s amid Hormuz-related supply concerns.

Related articles

$RTOHighAI 9/10

Rentokil Sells US Lake Management Arm To Bain Capital For $230m

Rentokil Initial (LSE: RTO) agreed to sell SOLitude Lake Management LLC to Bain Capital for $230m, with net proceeds of around $180m. SOLitude generated $112m revenue and $16m adjusted operating profit in FY2025. The deal is expected to close in Q4, subject to US antitrust approval. Rentokil plans to use proceeds to reduce leverage and fund growth, dividends, and potential shareholder returns.

$RTOMedAI 8/10

REG - Rentokil Initial PLC - Sale of SOLitude Lake Management, LLC

Rentokil Initial (RTO) agreed to sell SOLitude Lake Management, LLC to Bain Capital for $230m. The deal, expected to close in early Q4 2026, will yield net proceeds of around $180m. SOLitude generated $112m revenue and $16m adjusted operating profit in FY 2025. Rentokil plans to use proceeds to reduce leverage and invest in growth.

$AZNMedAI 8/10

Enhertu Extends PFS by Six Months in HER2 Lung Cancer

AstraZeneca (AZN) and Daiichi Sankyo's Enhertu showed a 6-month progression-free survival extension in a Phase III trial for HER2-mutant lung cancer, with a 37% reduced risk of disease progression or death. Median PFS was 14.3 months vs. 8.3 months for standard treatment. The trial enrolled patients with advanced non-small cell lung cancer. Enhertu's safety profile was consistent with prior data, with no new concerns. The drug is already approved for certain metastatic cancers.

$AZNMedAI 8/10

Add-on tozorakimab lowers exacerbation rate in adults with COPD, history of exacerbations

AstraZeneca's tozorakimab showed a lower annualized rate of moderate/severe COPD exacerbations vs. placebo in two phase 3 trials, according to data in The New England Journal of Medicine. The trials included over 1,700 patients with COPD and a history of exacerbations. The drug demonstrated efficacy across blood eosinophil counts and smoking status, with a favorable safety profile. AstraZeneca anticipates an FDA decision in Q1 2027.

$AZNHighAI 8/10

Two favorable EU opinions for AstraZeneca

The European Medicines Agency's CHMP recommended approval of AstraZeneca's Enhertu for early breast cancer treatment, potentially making it a new standard of care. The drug generated $1.8bn in 2025 revenue. The EMA also recommended approval for Klygefa, another AstraZeneca medicine. AstraZeneca shares were down 0.7% Monday, despite a 2.4% gain on Friday following the announcements.